Curasight's Cancer Platform Takes Center Stage at J.P. Morgan Week

COPENHAGEN, Denmark – January 05, 2026 – As the global healthcare industry converges on San Francisco for the 44th annual J.P. Morgan Healthcare Conference, Danish clinical-stage company Curasight A/S is preparing for a pivotal week of meetings with investors and industry leaders. The company's leadership, CEO Ulrich Krasilnikoff and CMO Prof. Andreas Kjær, will be present to discuss significant advancements in its innovative cancer-fighting platform, aiming to capture the attention and capital of a sector keenly focused on the next generation of oncology treatments.

Curasight arrives with powerful momentum, armed with fresh clinical progress updates. The discussions are expected to center on two key programs: the recent initiation of a Phase 1 trial of its therapeutic agent, uTREAT®, in patients with aggressive brain cancer, and the steady advancement of its diagnostic tool, uTRACE®, in a Phase 2 trial for prostate cancer. For a company at this stage, the J.P. Morgan conference week is more than a networking event; it's a critical venue to validate its science, strategy, and investment potential on a global stage.

A High-Stakes Pitch in San Francisco

The J.P. Morgan Healthcare Conference is widely regarded as the premier investment symposium for the biotechnology and pharmaceutical industries. For a clinical-stage firm like Curasight, securing meetings during this high-profile week is a strategic imperative. It offers an unparalleled opportunity to engage directly with a concentrated audience of financial analysts, venture capitalists, and potential pharmaceutical partners who are actively seeking to fund the next breakthroughs in medicine.

Attendance signals a company's readiness to play in the major leagues. The informal meetings that happen in hotel suites and conference rooms around Union Square are often where foundational conversations for future nine-figure licensing deals and crucial funding rounds begin. Curasight's presence is a clear statement of intent, positioning its uPAR theranostic platform not just as a scientific curiosity but as a commercially viable asset. The updates on its clinical trials provide the tangible evidence needed to transform investor interest into concrete financial commitments, which are the lifeblood for advancing costly clinical development programs toward regulatory approval and market launch.

The 'See and Treat' Strategy for Aggressive Cancers

At the heart of Curasight's strategy is its proprietary uPAR theranostic platform, a sophisticated, dual-pronged approach to fighting cancer. The platform targets the urokinase-type plasminogen activator receptor (uPAR), a protein highly expressed on the surface of many types of aggressive cancer cells but largely absent from healthy tissue. This high-contrast expression makes uPAR an ideal target for both pinpointing and attacking tumors.

The platform consists of two synergistic components:

• uTRACE® (The 'See' Component): This is a PET imaging agent designed to find and visualize uPAR-expressing cancers. By highlighting the tumor's location and, crucially, its level of aggressiveness, uTRACE® promises to provide clinicians with a non-invasive tool for more accurate diagnosis and risk stratification. This is particularly relevant in the company's ongoing Phase 2 trial for prostate cancer, where the goal is to help patients on active surveillance avoid unnecessary biopsies and treatments by better distinguishing slow-growing tumors from aggressive ones.

• uTREAT® (The 'Treat' Component): This is a targeted radiopharmaceutical therapy. It uses the same uPAR-targeting molecule as uTRACE® but is armed with a therapeutic radioisotope, Lutetium-177. Once injected, uTREAT® seeks out the uPAR-positive cancer cells and delivers a highly localized dose of cell-killing radiation, minimizing damage to surrounding healthy tissue. This approach is now being tested for the first time in humans in a Phase 1 trial for glioblastoma, one of the most aggressive and difficult-to-treat brain cancers. The first patient was safely dosed in December 2025, a landmark achievement that transitioned Curasight into a therapeutic clinical-stage company.

This integrated 'see and treat' paradigm, known as theranostics, represents a significant step toward personalized medicine. By first using uTRACE® to confirm the target is present, doctors can be more confident that uTREAT® will be effective, ensuring the right patient gets the right treatment.

Building Momentum with Strategic Alliances

Curasight's clinical progress is powerfully supported by a key strategic partnership with Curium Inc., a global leader in nuclear medicine. In May 2023, the two companies entered a global license and collaboration agreement for the development and commercialization of uTRACE®. Under the deal, Curasight is responsible for shepherding the diagnostic through clinical trials and regulatory approval, while Curium will leverage its vast infrastructure for manufacturing and worldwide commercialization.

This partnership provides crucial external validation for Curasight's technology and a clear path to market. It is also financially significant, with Curasight eligible for up to $70 million in milestone payments plus double-digit royalties on sales. The company has already received $1 million from two successfully achieved milestones related to manufacturing validation and patient enrollment in the Phase 2 prostate cancer trial. This non-dilutive funding complements the capital raised from public markets, including a rights issue in May 2025, and strengthens the company's financial footing as it advances its more capital-intensive therapeutic pipeline.

The company's stock (CPH: CURAS) has reflected this growing momentum, with its market capitalization showing significant growth over the past year. This performance, coupled with a steady stream of positive clinical news, provides a compelling narrative for the investor meetings in San Francisco.

Riding the Radiopharmaceutical Wave

Curasight is developing its platform at a time of explosive growth in the radiopharmaceutical market. Driven by the success of approved therapies and a deeper understanding of targeted radiation, the sector is attracting massive investment and M&A activity. Market research reports consistently project robust growth, with some estimates suggesting the market could swell from around $10 billion in 2024 to over $30 billion by the early 2030s, posting a compound annual growth rate well into the double digits.

This boom is fueled by a broader shift in oncology toward precision medicine. Radiopharmaceuticals like uTRACE® and uTREAT® are at the forefront of this trend, offering the potential for highly effective, personalized treatments with more manageable side-effect profiles than traditional chemotherapy or external beam radiation. The ability to target cancer at a molecular level is transforming treatment paradigms for diseases like prostate cancer and neuroendocrine tumors, and companies are racing to apply the concept to other malignancies.

By focusing on the well-documented uPAR target, which is implicated in numerous cancer types, Curasight's platform has broad potential applicability. Its progress in brain and prostate cancer serves as an important proof of concept, positioning the company as a significant player in this dynamic and rapidly expanding field of medicine. The discussions at J.P. Morgan will therefore not only be about Curasight's individual progress but also about how it fits into one of the most exciting growth stories in modern healthcare.